基因代理的抗糖尿病药物点和初级开放角度视光眼:孟德尔的随机化研究
Kefu Tang1, Wenqiu Wang2, Weiteng Chang3
1Department of Clinical Laboratory, Prenatal Diagnosis Center, Changning Maternity and Infant Health Hospital East China Normal University Shanghai China.
Health science reports
|October 25, 2024
概括
遗传分析表明,抑制ABCC8可能会降低欧洲人和东亚人的初级开角玻璃眼 (POAG) 风险. 这突出了ABCC8作为POAG的潜在治疗点,需要进一步研究其机制.
科学领域:
- 遗传学和眼科 医学
- 药物基因组学 药物基因组学
- 玻璃眼研究研究 玻璃眼研究
背景情况:
- 观察性研究表明,抗糖尿病药物可能会降低初级开角玻璃眼 (POAG) 风险,但因果关系尚未被证明.
- 药物点的遗传变异可以作为药物的长期影响的代理.
- 调查抗糖尿病药物点的遗传代理可以提供对POAG风险的见解.
研究的目的:
- 用孟德尔随机化评估抗糖尿病药物标对POAG风险的潜在影响.
- 评估ABCC8,PPARG,GLP1R和SLC5A2基因变异对欧洲和东亚人群中POAG的影响.
主要方法:
- 进行了一项双样本的门德尔随机化研究.
- 与HbA1c相关的遗传变异被用作抗糖尿病药物点的代理.
- 来自大型联盟 (IGG,GBMI,FinnGen) 的POAG遗传总结统计数据分别对欧洲人和东亚人进行了分析.
主要成果:
- 一致的证据表明,ABCC8抑制对数据集中的POAG风险具有保护作用.
- 在欧洲人 (OR=0.211) 和东亚人 (OR=0.070) 中,基因预测的ABCC8抑制显著降低了POAG风险.
- 保护性关联主要通过眼内压进行介导;对于PPARG,SLC5A2或GLP1R没有发现显著的关联.
结论:
- 在欧洲和东亚人口中,基因代理的ABCC8抑制显示出对POAG的保护作用.
- ABCC8成为POAG.的有希望的药物标.
- 建议对ABCC8的保护作用背后的机制进行进一步研究.
关键词:
ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC8ABCC is also known by the name of门德尔的随机化抗糖尿病药物 药物 抗糖尿病药物主要的开角绿眼 glaucoma 的情况.相关概念视频
Open Angle Glaucoma: Treatment
397
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
397
Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
161
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
161
Angle Closure Glaucoma: Treatment
441
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
441


